Orphan drugs price changes U.S. 2012-2014

This statistic depicts the cumulative percentage increase in price for select orphan drugs in the United States between 2012 and 2014. According to the data, orphan drug Gralise has increased in price by 113.5 percent over the given period.

Percentage cumulative price change among select orphan drugs in the U.S. between 2012 and 2014

Characteristic	Price increase
Gralise	113.5%
Horizant*	112.8%
Sabril	95.3%
Adcirca	86%
Banzel	76.1%
Zirgan	62.9%
Humira	62.5%
Gleevec	58.3%
Xenazine	48.2%
Votrient	45.5%
Ampyra	41.1%
Afinitor	40.8%
Promacta	33.7%
Kalbitor	33.3%
Coartem	32.7%
Jakafi	31%
Remicade	30.7%
Onfi	30.5%
Ferriprox	30.3%
Berinert	27.3%
Sensipar	26.1%
Xalkori	25.2%
Viread	20%
Firazyr	17.7%
Caprelsa	15.7%
Nplate	15.6%
Zelboraf	15.4%
Herceptin	15.1%
Rituxan	14.5%
Cayston	14.3%
Cuvposa	14.3%
Cinryze	13.8%
Colcrys	12.3%
Avastin	11.2%
Tyvaso	10.7%
Soliris	8.4%
Iclusig**	8%
Velcade	7.7%
Kalydeco	4.5%
Mozobil	4%
Gamunex	2.8%
Xiaflex	2.5%
Vpriv	2%
Lumizyme***	1.8%
Makena	0%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

October 2016

More information

Region

United States

Survey time period

01 January 2012 to 31 December 2014

Supplementary notes

* The cumulative price change is based on changes in the unit price for NDC #00173-0806-01 & #53451-0101-01.
** As Iclusig was not approved by the FDA until December, 2012 it was included in the study; however, its pricing and utilization data were from 2013 to 2014 only.
*** Includes patients prescribed Myozyme.

Citation formats